Takara Bio strengthens its IP position on single cell RNA-seq

Takara Bio USA, Inc has announce that patent JP6336080B—covering the Smart-seq2 method, developed by Rickard Sandberg and exclusively licensed to TBUSA by the Ludwig Institute—has been awarded by the Japan Patent Office. Additional patents regarding the Smart-seq2 technology are pending in the U.S. and other regions.

Because our scientists are dedicated to developing solutions for next-generation sequencing of challenging and low-input sample types, in 2015 TBUSA entered into an agreement with Ludwig Cancer Research to exclusively license the Smart-seq2 method. This advancement further bolstered our portfolio of NGS products, already powered by our proprietary SMART® (Switching Mechanism at 5′ end of RNA Template) technology which enables sensitive and robust sequencing of single-cell or ultra-low-input RNA samples.

“We remain focused on pushing the envelope of single-cell RNA-seq technology, and we are strongly committed to providing novel technologies for this rapidly evolving field,” said Carol Lou, President of Takara Bio USA, Inc. “Our license on the gold-standard Smart-seq2 method enables us to further improve upon our original methods and allows researchers to push the limits of their own work.”

For more information about TBUSA products for next-generation sequencing, please visit: takarabio.com/products/next-generation-sequencing.

Source – PR Newswire

Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.